Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
MINIZIDE is a fixed-dose combination oral capsule containing polythiazide (a thiazide diuretic) and prazosin hydrochloride (an alpha-1 adrenergic antagonist) approved in 1980 for hypertension management. The combination works synergistically: prazosin provides direct vasodilation and alpha-blockade while polythiazide enhances sodium and water excretion to reduce blood volume and peripheral resistance. This dual mechanism addresses multiple pathways in hypertension control.
Product is in late-stage lifecycle with declining market presence; commercial teams should focus on managed transition and retention strategies rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MINIZIDE offers limited career acceleration; the product is in late-stage lifecycle with no linked job openings and declining market relevance. Professionals on this team typically focus on compliance, physician relationship maintenance, and managed decline strategies rather than innovation or market expansion.
Worked on MINIZIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.